Dr. Mohindru has served as our Interim Chief Executive Officer since January 2026, President and Chief Executive Officer since late March 2026 and has been a director since 2021. She is a co-founder and Board Chair of Roshon Therapeutics, Inc., an early-stage, private biotech company developing antibodies for the treatment of cancer and inflammatory diseases.
Previously, Dr. Mohindru was CEO and Board Director of Novasenta Inc., an oncology-focused biotech company. Dr. Mohindru previously worked in executive roles at several additional biotechnology companies, having served as Chief Executive Officer of CereXis, Inc., Chief Financial Officer and Chief Strategy Officer of Cara Therapeutics, Inc. (Nasdaq: CARA), and Chief Strategy Officer at Curis, Inc (Nasdaq: CRIS). Prior to her leadership roles in the biotechnology industry, Dr. Mohindru spent several years as an equity research analyst covering the biotechnology sector at UBS, Credit Suisse and ThinkEquity.
In addition to her position at Cardiff Oncology, Dr. Mohindru serves as a member of the Board of Directors at CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage biopharmaceutical company. She was previously a member of the Board of Directors of SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company. Dr. Mohindru received her Ph.D. in Neurosciences from Northwestern University and her master’s in biotechnology and B.S. in Human Biology (Hons) from the All India Institute of Medical Sciences.
What is Mani Mohindru's net worth?
The estimated net worth of Mani Mohindru is at least $79.15 thousand as of July 14th, 2026. Mohindru owns 59,067 shares of Cardiff Oncology stock worth more than $79,150 as of September 15th. This net worth estimate does not reflect any other assets that Mohindru may own. Learn More about Mani Mohindru's net worth.
How do I contact Mani Mohindru?
Has Mani Mohindru been buying or selling shares of Cardiff Oncology?
Mani Mohindru has not been actively trading shares of Cardiff Oncology during the past quarter. Most recently, on Thursday, June 18th, Mani Mohindru bought 24,703 shares of Cardiff Oncology stock. The stock was acquired at an average cost of $1.21 per share, with a total value of $29,890.63. Following the completion of the transaction, the chief executive officer now directly owns 24,703 shares of the company's stock, valued at $29,890.63. Learn More on Mani Mohindru's trading history.
Who are Cardiff Oncology's active insiders?
Are insiders buying or selling shares of Cardiff Oncology?
In the last year, Cardiff Oncology insiders bought shares 2 times. They purchased a total of 54,703 shares worth more than $66,490.63. The most recent insider tranaction occured on June, 18th when Director
Gary W. Pace bought 30,000 shares worth more than $36,600.00. Insiders at Cardiff Oncology own 8.8% of the company.
Learn More about insider trades at Cardiff Oncology. Information on this page was last updated on 6/18/2026.
